nVerses Capital’s Avita Medical RCEL Stock Holding History

nVerses Capital’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-900	Closed	-$9.65K	–	688
2024 Q3	$9.65K	Buy	+900	New	+$8.45K	﹤0.01%	897

Other funds holding RCEL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

nVerses Capital's RCEL Position: Q4 2024 in Review

nVerses Capital sold out of Avita Medical (RCEL) in Q4 2024, closing a stake of 900 shares — an estimated $9.65K sold.

nVerses Capital first reported a position in RCEL in Q3 2024 and held it in 1 quarter. The position peaked at $9.65K in Q3 2024. 73 funds tracked by Wall St. Rank hold RCEL as of Q4 2024.

nVerses Capital reported no remaining Avita Medical position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 900 Avita Medical shares in Q4 2024, an estimated $9.65K.
nVerses Capital first reported a position in Avita Medical in Q3 2024 and held it in 1 quarter.
nVerses Capital's Avita Medical position peaked at $9.65K in Q3 2024.
73 funds tracked by Wall St. Rank held Avita Medical as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.